


OVERVIEW

PRESS RELEASES **EVENTS & PRESENTATIONS** CORPORATE GOVERNANCE MANAGEMENT BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT THE BOARD FINANCIAL INFORMATION SEC FILINGS ANNUAL REPORTS QUARTERLY RESULTS STOCK INFORMATION HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE INVESTOR FAQS CONTACT US

EMAIL ALERTS



# **Investor Relations**

Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use

CONTAGIOUS ideas

To Drive Therapy Compliance

in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.

# STOCK QUOTE


Price Change High

May 18, 2018 9:48 AM EDT

VIEW DETAILS

Copyright Nasdaq. Minimum 15 minutes delayed.

## STOCK CHART



# **PRESS RELEASES**

May 11, Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance

May 08, 2018 Melinta Therapeutics Reports First Quarter 2018 Financial Results

May 08, 2018 Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting

## **EVENTS & PRESENTATIONS**

FILTER

May 08, 2018

Melinta Therapeutics Q1 2018 Earnings Call

RESET

CLICK HERE FOR WEBCAST

Mar 27, 2018

Melinta Therapeutics, Inc. at the Needham & Company's 17th Annual Healthcare Conference

CLICK HERE FOR WEBCAST

Mar 13, 2018

Melinta Therapeutics Q4 2017 Earnings Call

CLICK HERE FOR WEBCAST

Melinta Therapeutics, Inc. ©2018 ALL RIGHTS RESERVED | Terms of Use